Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma

Ting Lu; Yan Liu; Shuang Yu; Congcong Yin; Peng Li; Jingjing Ye; Daoxin Ma; Chunyan Ji

doi:10.18632/oncotarget.10966

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma

Ting Lu, Yan Liu, Shuang Yu, Congcong Yin, Peng Li, Jingjing Ye, Daoxin Ma and Chunyan Ji _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:56574-56583. https://doi.org/10.18632/oncotarget.10966

Metrics: PDF 1703 views | HTML 2597 views | ?

Abstract

Ting Lu1,*, Yan Liu1,*, Shuang Yu1, Congcong Yin1, Peng Li1, Jingjing Ye1, Daoxin Ma1, Chunyan Ji1

1Department of Hematology, Qilu Hospital, Shandong University, Jinan, PR China

*These authors contributed equally to this work

Correspondence to:

Chunyan Ji, email: [email protected]

Keywords: B-cell non-Hodgkin’s lymphoma, Th22, IL-22, prognosis

Received: November 23, 2015 Accepted: July 18, 2016 Published: July 30, 2016

ABSTRACT

T helper (Th) 22 cells play important roles in the pathogenesis of autoimmune and inflammatory diseases, and their function in tumors remains uncertain. In the current study, we investigated the alternations and clinical significance of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma (B-NHL). We found that the frequency of Th22 cells was significantly elevated in peripheral blood of newly-diagnosed B-NHL patients, and returned to normal level after chemotherapy. In consistent with increased Th22 frequency, plasma IL-22 and IL-6 levels in B-NHL patients were remarkably increased. Moreover, the increased Th22 frequency was associated with the older age (> 60 yr) and a poorer response to therapy in B-NHL patients. In addition, there existed a statistically positive correlation between circulating Th22 and Th17 frequencies in B-NHL patients. Our data demonstrated that circulating Th22 frequency was associated with the clinical outcome and prognosis of B-NHL patients, indicating that Th22 immune response might play an important role in the development and progression of B-NHL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10966

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma

Abstract